Cargando…
Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic
Adenoviral vectors have been explored as vaccine agents for a range of infectious diseases, and their ability to induce a potent and balanced immune response made them logical candidates to apply to the COVID-19 pandemic. The unique molecular characteristics of these vectors enabled the rapid develo...
Autores principales: | Mendonça, Samir Andrade, Lorincz, Reka, Boucher, Paul, Curiel, David T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342436/ https://www.ncbi.nlm.nih.gov/pubmed/34354082 http://dx.doi.org/10.1038/s41541-021-00356-x |
Ejemplares similares
-
HLA and PF4 antibody production after adenoviral vector SARS-CoV-2 vaccination
por: Bouayad, Abdellatif
Publicado: (2021) -
Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies
por: Tada, Takuya, et al.
Publicado: (2022) -
Adenoviral Vector DNA- and SARS-CoV-2 mRNA-Based Covid-19 Vaccines: Possible Integration into the Human Genome - Are Adenoviral Genes Expressed in Vector-based Vaccines?
por: Doerfler, Walter
Publicado: (2021) -
Adenoviral Vector-Based Vaccine Platforms for Developing the Next Generation of Influenza Vaccines
por: Sayedahmed, Ekramy E., et al.
Publicado: (2020) -
Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status
por: Chavda, Vivek P., et al.
Publicado: (2023)